Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% of ...

Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...

Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...

The future holds promise for robots to actively collaborate in diverse aspects of human endeavor, transforming industries ...